KUX 1151
Alternative Names: KUX-0511; KUX-1151Latest Information Update: 05 Nov 2023
At a glance
- Originator Kissei Pharmaceutical
- Class Antigouts
- Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gout; Hyperuricaemia
Most Recent Events
- 27 Sep 2021 Discontinued - Phase-II for Gout in Japan (PO)
- 27 Sep 2021 Discontinued - Phase-II for Hyperuricaemia in Japan (PO)
- 01 Jul 2014 Phase-II clinical trials in Gout in Japan (PO)